NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: VAISHALI · data 2026-10-30
Vaishali Pharma Ltd.
In plain words
Price: 37.5% below its 52-week high of ₹10.27.
Delivery: 66.5% of traded shares were kept for delivery over the last 10 sessions, against 69.1% over the last 60.
Latest results: a net profit of ₹2 cr for the quarter ended Jun 2026 (+21.1% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹108 cr |
| Net profit (last 12 months) | ₹4 cr |
| Sales growth, 3 years (yearly) | 15.8% |
| Profit growth, 3 years (yearly) | -14.2% |
At a glance
Promoters 31.6% (+5.3 pts in a year), pledged 0.0%.
P/E 19.6, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 6.2%, ROCE 3.6%, operating margin 3.4%: how much profit it earns on the money it uses.
Debt/equity 0.27, Profit growth -14.2% and sales growth 15.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Promoters raised their holding by 5.3 points in a year.
- Low return on equity (6.2%).
- Thin operating margin (3.4%).
- Profit fell 14.2% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
VAISHALI Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹22.89 crore, down 15% QoQ.
Net profit was ₹1.55 crore, up 307.9% QoQ.
Operating margin was 6.5%.
EPS was ₹0.12, up 300% QoQ.
VAISHALI के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹22.89 करोड़; पिछली तिमाही की तुलना में 15% की गिरावट।
शुद्ध मुनाफ़ा: ₹1.55 करोड़; पिछली तिमाही की तुलना में 307.9% की बढ़त।
ऑपरेटिंग मार्जिन: 6.5%।
EPS: ₹0.12; पिछली तिमाही की तुलना में 300% की बढ़त।
VAISHALIના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹22.89 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 15% ઘટાડો.
ચોખ્ખો નફો: ₹1.55 કરોડ; ગયા ક્વાર્ટરની સરખામણીએ 307.9% વધારો.
ઓપરેટિંગ માર્જિન: 6.5%.
EPS: ₹0.12; ગયા ક્વાર્ટરની સરખામણીએ 300% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 65.9% over the last 20 sessions vs 69.8% in the 40 before (0.94x); shares delivered per day 0.78x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results
- 14 Aug 26Results Q1 FY27 results: net profit ₹1.6 cr -1.5% next session
- 30 Jun 26Results Q4 FY26 results: net profit ₹0.4 cr -0.8% next session
- 13 Feb 26Results Q3 FY26 results: net profit ₹1.3 cr +1.5% next session
- 14 Nov 25Results Q2 FY26 results: net profit ₹1.2 cr -0.6% next session
- 11 Aug 25Results Q1 FY26 results: profit −24.7% YoY -1.8% next session
- 28 May 25Results Q4 FY25 results: loss narrowed vs a year ago -1.2% next session
- 6 Feb 25Results Q3 FY25 results: profit −31.8% YoY -1.9% next session
- 14 Nov 24Results Q2 FY25 results: profit +15.9% YoY -4.3% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹23 cr | ₹2 cr | +21.1% | 6.5% | 0.12 |
| Mar 2026 | ₹27 cr | ₹0 cr | — | -0.8% | 0.03 |
| Dec 2025 | ₹25 cr | ₹1 cr | -8.3% | 6.3% | 0.1 |
| Sept 2025 | ₹33 cr | ₹1 cr | -39.6% | 4.2% | 0.09 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 31.61% | 31.61% | 31.61% | 31.61% |
| Foreign institutions (FII) | — | — | — | — |
| Domestic institutions (DII) | — | — | — | — |
| Mutual funds | — | — | — | — |
| Retail investors | 28.04% | 28.14% | 26.95% | 26.92% |
| Number of shareholders | 26,702 | 26,671 | 26,534 | 27,148 |
Common questions
What was Vaishali Pharma Ltd.'s latest quarterly profit?
Vaishali Pharma Ltd. reported a net profit of ₹2 cr for the quarter ended Jun 2026 (+21.1% on the same quarter a year earlier), on revenue of ₹23 cr.
How much do promoters hold in Vaishali Pharma Ltd.?
Promoters held 31.61% of Vaishali Pharma Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Vaishali Pharma Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.27.
What is Vaishali Pharma Ltd.'s P/E ratio?
About 19.6, based on the last 12 months' earnings and a price of ₹6.42 (data 2026-10-30).
What is the 52-week high and low of Vaishali Pharma Ltd.?
The 52-week high is ₹10.27 and the 52-week low is ₹4.75.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Vaishali Pharma Ltd. | ₹6.42 | ₹92 cr | 19.6 | — | 6.2% | 3.6% | 0.27 | -37.1% |
| Parnax Lab Limited | ₹109.5 | ₹122 cr | 14.1 | — | 13.2% | 18% | 0.87 | +1.4% |
| Sotac Pharmaceuticals Limited | ₹111.65 | ₹123 cr | 21.4 | 2.1 | 10.3% | 17.4% | 0.64 | -6.1% |
| Makers Laboratories Ltd | ₹200.9 | ₹119 cr | 34.7 | — | 3.3% | 7.3% | 0.08 | +22.1% |
| Alpa Laboratories Limited | ₹50.38 | ₹105 cr | 24.2 | — | 8.4% | 0.7% | 0.01 | -45.2% |
| Sunil Healthcare Ltd. | ₹61.55 | ₹70 cr | 17.7 | — | 5.9% | 6% | 0.8 | -13.3% |
Compare VAISHALI with PARNAXLAB in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open VAISHALI in NSE Scanner →